Gufic BioSciences Ltd
Gufic BioSciences Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
2 of 3 strong
Not discussed on this call: fundraise, order book.
The short version
Company targets 15% to 20% year-over-year revenue growth as a bare minimum, with efforts ongoing to exceed 20% growth. The company targets a year-on-year growth of 15% to 20% as a bare minimum, with efforts underway to exceed 20%.
From Gufic BioSciences Ltd's Q1 FY27 earnings-call transcript · updated 26 Aug 2026.
Revenue & Sales Performance
- Company targets 15% to 20% year-over-year revenue growth as a bare minimum, with efforts ongoing to exceed 20% growth.
- Indore facility capacity utilization is expected to increase from around 30-35% to close to 80% in the next 2-3 years, improving operating leverage.
- Revenue extraction from Indore alone is projected between INR 800 crores to INR 1,200 crores without additional capex.
- Overall revenue potential combining existing product mix and legacy capacity is estimated between INR 1,600 crores to INR 2,000 crores.
- Product mix improvements aiming to increase average revenue per vial from INR 80-100 to INR 300-500 to drive further growth.
- Expansion into complex injectables, depot, and liposomal products expected to contribute 20-30% of production by FY28.
- Growth from in-licensing and transition from B2B to B2C sales models in emerging markets (Africa, Southeast Asia) will enhance revenue.
- New product lines (e.g., aesthetics fillers, botulinum toxin) and GLP-1 CMO operations are expected to add to growth trajectory.
Profitability & Margins
See what Gufic BioSciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Current capex around INR 300 crore mainly for Indore and Navsari facilities.
- No major new infrastructure or equipment capex planned; focus is on adding new product lines (depot and liposomal injections) within existing capex.
- Capacity expansion by introducing depot and liposomal products in lyophilization lines.
- Indore plant fully operational; ongoing validation batches for depot and liposomal products.
- Strategic focus on shifting product mix to higher-value complex injectables and specialty products to improve revenue per vial.
- No significant capital expenditure planned for botulinum toxin portfolio; progressing through supply and regulatory steps without major capex.
- Potential future capex tied to scaling exports and EU certification but not explicitly detailed.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Gufic BioSciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Gufic BioSciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹231 Cr, net profit ₹12 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Gufic BioSciences Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
- IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Frequently Asked Questions
What were Gufic BioSciences Ltd Q1 FY27 results?
Company targets 15% to 20% year-over-year revenue growth as a bare minimum, with efforts ongoing to exceed 20% growth. The company targets a year-on-year growth of 15% to 20% as a bare minimum, with efforts underway to exceed 20%.
What is Gufic BioSciences Ltd share price analysis?
Gufic BioSciences Ltd currently shows a below-average growth signal. The stock trades at a P/E of 58.9 with a market cap of ₹4,327 Cr. Investors should review the full earnings analysis for detailed insights.
Is Gufic BioSciences Ltd planning capital expenditure?
Current capex around INR 300 crore mainly for Indore and Navsari facilities.
Keep Gufic BioSciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.